利福霉素与阿片类药物联用的临床结局:系统综述
该系统综述依据PRISMA标准检索PubMed、Scopus和OVID Embase至2020年1月,最终纳入12篇全文文献。利福平(11篇,92%)和利福布汀(2篇,17%)与七种阿片类药物联用,多数组合显示阿片效应降低,仅利福平联合颊用芬太尼及利福布汀联合丁丙诺啡或美沙酮未见可测量的临床相互作用。
要点
- 利福平与美沙酮联用可致戒断症状,与曲马多、吗啡、羟考酮联用可降低镇痛效果。
- 利福平联合颊用芬太尼、利福布汀联合丁丙诺啡或美沙酮未发现可测量的临床相互作用。
- 现有文献缺乏剂量调整等具体干预策略,需进一步研究。
核心结论
- 现有文献提示利福霉素联用可降低阿片类药物的临床效应。
研究设计与样本
- 遵循PRISMA标准的系统综述,检索PubMed、Scopus和OVID Embase自建库至2020年1月,从2260条引文中纳入12篇全文同行评议英文文献。
主要发现
- 利福平(11篇,92%)和利福布汀(2篇,17%)与七种不同阿片类药物联用。
- 利福平联用美沙酮出现戒断症状,联用曲马多、吗啡和羟考酮(尤其显著)镇痛效果降低。
- 仅利福平联合颊用芬太尼、利福布汀联合丁丙诺啡和美沙酮未发现可测量的临床相互作用。
临床怎么用
- 临床联用利福霉素与阿片类药物时需警惕阿片效应降低,尤其美沙酮、曲马多、吗啡和羟考酮。
- 对利福平联合颊用芬太尼、利福布汀联合丁丙诺啡或美沙酮的患者,可关注其相互作用风险较低。
局限性
- 文献仅纳入英文全文同行评议文章,可能存在选择偏倚。
- 缺乏剂量调整等具体干预策略的研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Opioids are one of the most prescribed classes of analgesic medications. Their narrow therapeutic index and metabolism through cytochrome p450 (CYP) enzymes can result in a drug interaction when used concomitantly with rifamycins. In clinical scenarios where concurrent therapy with an opioid and a rifamycin occurs, there is no standardized guidance for managing the interaction. The objective of this review was to examine literature which evaluates the concomitant use of opioids and rifamycins with clinically relevant CYP-inducing properties. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria was performed. PubMed, Scopus, and OVID Embase were queried for studies from database inception to January 2020 related to rifamycin and opioid medications. Only full-text, peer-reviewed, English language articles addressing clinical outcomes from concomitant rifamycin and opioid therapy were included. The review isolated 12 articles for data extraction from an original 2260 citations identified. Rifampin (11; 92%) and rifabutin (2; 17%) were the rifamycins studied along with seven different opioids. Decreased effect of opioids with concomitant rifampin therapy manifested as withdrawal in numerous patients on methadone and a decreased analgesic effect from tramadol, morphine, and, most notably, oxycodone. Only the combinations of rifampin with buccal fentanyl and rifabutin with buprenorphine and methadone were found to have no clinically measurable interaction. Available literature suggests that a decrease in opioid clinical effects is appreciated with concomitant rifamycin therapy. Further research is needed to focus on specific mitigation strategies beyond opioid agent selection, such as dosing adjustment recommendations.
引用
- Kinney EM, Vijapurapu S, Covvey JR, et al. Clinical outcomes of concomitant rifamycin and opioid therapy: A systematic review. Pharmacotherapy. 2021. PMID: 33748959. doi:10.1002/phar.2520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。